Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. Clinical Medicine / 臨床醫學研究所
  4. Exploring new therapies for a serological cure of chronic hepatitis B
 
  • Details

Exploring new therapies for a serological cure of chronic hepatitis B

Journal
Hepatitis B Virus and Liver Disease
Pages
343-353
Date Issued
2018
Author(s)
Horng J.-H.
Wu C.-R.
PEI-JER CHEN  
DOI
10.1007/978-981-10-4843-2_17
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045867480&doi=10.1007%2f978-981-10-4843-2_17&partnerID=40&md5=81cd5bb25af4856d205d3561030460ea
https://scholars.lib.ntu.edu.tw/handle/123456789/568350
Abstract
Chronic hepatitis B is a global health issue, as WHO estimates about 240 millions in the world. Without antiviral therapies, a quarter of the HBV carriers will eventually succumb to cirrhosis or hepatocellular carcinoma (Fattovich et al. 2004; Di Bisceglie 2009; Beasley 1988; Liaw et al. 1988). Active therapies have been developed, such as pegylated interferon and antiviral nucleos(t)ide analogs, in the last 20 years (Belloni et al. 2012; Papatheodoridis et al. 2002; Lau et al. 2005). Despite of an effective control of HBV replication by long-term NA treatments, the success of eliminating intrahepatic HBV or infected hepatocytes remains low (about 1-10% of treated patients). A search for novel, curative antiviral therapies has been actively taken up in many institutes. Practically, current NA therapies effectively eliminate extracellular virions, and so the next step will be to eliminate the intracellular viral RNAs, viral proteins, or eventually viral DNAs. The theme has become a more and more important medical task, especially after the advent of highly effective direct antiviral agents curing essentially hepatitis C. Therefore, there are many excellent reviews on the HBV life cycle or immunology that point out or summarize possible targets for future antiviral development (Lanford et al. 2013; Isogawa et al. 2005; Ma et al. 2015; Tang et al. 2016; Petersen et al. 2016). This chapter will skip these overlapping parts but only describe certain exploratory experiments toward novel targets ongoing. The main approach is to develop antiviral immunotherapies which can eradicate intrahepatic HBV DNAs or the HBV-infected hepatocytes in the near future. ? Springer Nature Singapore Pte Ltd. 2018. All rights reserved.
Subjects
Antiviral agent development; Core protein allosteric modulators; Curative antiviral therapy; HBV; Immune checkpoint blockers; Kinase inhibitors
SDGs

[SDGs]SDG3

Publisher
Springer Singapore
Type
book part

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science